» Articles » PMID: 33643266

Codon Usage and Adenovirus Fitness: Implications for Vaccine Development

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2021 Mar 1
PMID 33643266
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccination is the most effective method to date to prevent viral diseases. It intends to mimic a naturally occurring infection while avoiding the disease, exposing our bodies to viral antigens to trigger an immune response that will protect us from future infections. Among different strategies for vaccine development, recombinant vaccines are one of the most efficient ones. Recombinant vaccines use safe viral vectors as vehicles and incorporate a transgenic antigen of the pathogen against which we intend to generate an immune response. These vaccines can be based on replication-deficient viruses or replication-competent viruses. While the most effective strategy involves replication-competent viruses, they must be attenuated to prevent any health hazard while guaranteeing a strong humoral and cellular immune response. Several attenuation strategies for adenoviral-based vaccine development have been contemplated over time. In this paper, we will review them and discuss novel approaches based on the principle that protein synthesis from individual genes can be modulated by codon usage bias manipulation. We will summarize vaccine approaches that consider recoding of viral proteins to produce adenoviral attenuation and recoding of the transgene antigens for both viral attenuation and efficient viral epitope expression.

Citing Articles

Host and structure-specific codon usage of G genotype (VP7) among group A rotaviruses.

Liu Z, Zhao S, Jin X, Wen X, Ran X Front Vet Sci. 2024; 11:1438243.

PMID: 39582884 PMC: 11582040. DOI: 10.3389/fvets.2024.1438243.


Protective efficacy of a recombinant adenovirus expressing novel dual F and HN proteins of bovine parainfluenza virus type 3.

Zhang J, Wu J, Zhu Q, Huang X, Zhang Z, Zhu C Vet Res. 2024; 55(1):144.

PMID: 39511676 PMC: 11545272. DOI: 10.1186/s13567-024-01400-z.


A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variants.

Liu X, Ng W, Zusinaite E, Freitas J, Taylor A, Yerragunta V Nat Commun. 2024; 15(1):7225.

PMID: 39187479 PMC: 11347628. DOI: 10.1038/s41467-024-51535-y.


Application of codon usage and context analysis in genes up- or down-regulated in neurodegeneration and cancer to combat comorbidities.

Khandia R, Pandey M, Zaki M, Al-Hussain S, Baklanov I, Gurjar P Front Mol Neurosci. 2023; 16:1200523.

PMID: 37383425 PMC: 10293642. DOI: 10.3389/fnmol.2023.1200523.


Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status.

Chavda V, Bezbaruah R, Valu D, Patel B, Kumar A, Prasad S Vaccines (Basel). 2023; 11(2).

PMID: 36851309 PMC: 9965371. DOI: 10.3390/vaccines11020432.


References
1.
Nunez-Manchon E, Farrera-Sal M, Otero-Mateo M, Castellano G, Moreno R, Medel D . Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses. NAR Cancer. 2021; 3(2):zcab015. PMC: 8210037. DOI: 10.1093/narcan/zcab015. View

2.
Schone D, Hrycak C, Windmann S, Lapuente D, Dittmer U, Tenbusch M . Immunodominance of Adenovirus-Derived CD8 T Cell Epitopes Interferes with the Induction of Transgene-Specific Immunity in Adenovirus-Based Immunization. J Virol. 2017; 91(20). PMC: 5625516. DOI: 10.1128/JVI.01184-17. View

3.
Feng L, Wang Q, Shan C, Yang C, Feng Y, Wu J . An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Commun. 2020; 11(1):4207. PMC: 7442803. DOI: 10.1038/s41467-020-18077-5. View

4.
Coughlan L . Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines. Front Immunol. 2020; 11:909. PMC: 7248264. DOI: 10.3389/fimmu.2020.00909. View

5.
Li L, Petrovsky N . Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines. 2015; 15(3):313-29. PMC: 4955855. DOI: 10.1586/14760584.2016.1124762. View